Bapineuzumab for Alzheimer's Disease Goes To Phase 3

Armen Hareyan's picture
Advertisement

Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today announced encouraging preliminary findings from a Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer's disease.

Advertisement